v3.26.1
Segment Reporting
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting
Note 9—Segment Reporting
 
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (the “CODM”), or decision-making group, in deciding how to allocate resources in assessing performance. Nuwellis has one reportable segment: fluid overload. The Company is a medical technology company focused on developing and commercializing the Aquadex System. The Company recognizes this medical device system as one reporting segment. The CODM is the chief executive officer.
 
The accounting policies of the fluid overload segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the fluid overload segment based on net loss, which is reported on the statement of operations as consolidated net loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. The Company does not have any intra-entity sales or transfers.
 
The CODM uses cash forecast models in deciding how to invest into the fluid overload segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net income (loss) is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management’s compensation.
 
The table below summarizes the significant expense categories regularly reviewed by the CODM for the six months ended June 30, 2026 and 2025 (amounts in thousands):
 
                 
    Three months ended
June 30
 
      Six months ended
June 30
 
    2026     2025     2026     2025  
Revenue
 $1,969   $1,725   $4,372   $3,629 
Gross Profit
  1,498    958    3,182    2,025 
Gross profit %
  76.1%   55.5%   72.8%   55.8%
Operating expenses:
                   
General and administrative
  1,524    1,347    3,633    3,189 
Sales and marketing
  1,984    1,598    4,066    3,028 
Development
  431    327    1,660    533 
Clinical, Quality, Regulatory
  706    575    1,513    1,157 
Total operating expenses
  4,645    3,847    10,872    7,907 
Stock Based Compensation
  22    17    47    84 
Other Expense
  1,659    9,647    1,632    9,601 
Net loss
 $(4,828  $(12,553  $(9,369  $(15,567